Tag:

Bayer

Latest Headlines

Latest Headlines

U.K. watchdogs back Bayer's Xarelto for heart attack patients

Bayer's Xarelto, which has been cruising along since it joined a new class of warfarin replacement therapies on the market, has faced a rare stumbling block in acute coronary syndrome--an indication the FDA has denied it on three separate occasions. But across the pond, it's picked up a nod in some ACS patients from the U.K.'s cost-effectiveness gatekeeper.

Regeneron's Eylea bests Lucentis, Avastin in diabetic eye disease, NIH study finds

Regeneron and Bayer's Eylea has been racking up sales that have consistently topped analyst expectations since its U.S. rollout in late 2011. Now, new data may help it potentially top them in a market Novartis and Roche got to first.

Bayer insists its probiotic marketing claims aren't full of hot air

Last month, the feds took issue with Bayer's marketing for its Phillips' Colon Health product, saying the company's claims lacked scientific backing. But the way the German pharma sees it, the legal standard the DOJ is holding it to is not only unfair, it's unprecedented.

Bayer goes Glamour-ous with 'Girls' star for new IUD campaign

Hey, young women: You have plans. Dreams. Goals. And by the way, getting pregnant unexpectedly could throw those visions for your future under the bus. That's the (implicit) message in several newly launched campaigns from Pfizer and Bayer Healthcare, including a pitch for Bayer's new device Skyla supported by a fellow millennial, the actress Zosia Mamet of Girls fame.

Will Zoetis stand alone when Big Pharma's music stops?

After standing alone atop the animal health industry since being spun off by Pfizer last year, the question now circulating is if Zoetis will be a target of Bayer now that the German pharmaceutical company's coffers look like they may become flush with cash.

Eylea gets yet another approval, this one in Japan

The approvals, and the sales, just keep piling up for Eylea, the blockbuster that Bayer shares with developer Regeneron. Just weeks after getting an important nod in Europe, it has won approval in Japan, the world's third largest market, for use in myopic choroidal neovascularization.

Analysts: Bayer could use plastics proceeds to fund a deal for Zoetis

Now that Bayer has announced a planned spinoff of its plastics business, all eyes are on what it may do with the proceeds. And the way some analysts see it, that money could go toward a pickup of animal health company Zoetis.

Bayer brings $12.9B plastics spinoff to Big Pharma's slim-down party

Bayer's drug business is booming. So much so that the German company has decided to put its focus squarely on its life sciences division: It plans to spin off its plastics unit within 18 months, taking a lead from its Big Pharma peers with the industry's latest slim-down move.

J&J, Bayer look to turbocharge Xarelto with new label-expanding studies

Johnson & Johnson and Bayer's Xarelto already heads up the pack of new-age anticoagulants, but the pair isn't quitting while it's ahead. Instead, the drugmakers are looking to expand that market lead with new clinical trials aimed at widening the drug's label.

Bloomberg: Sale of OTC specialist Omega could top $5.3B with bids from Bayer, Sanofi

What's an OTC drugmaker worth in the race to the top of the consumer healthcare space? Potentially more than $5.3 billion, if that drugmaker is Belgium's Omega Pharma.